Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial

In this multicenter, single-arm phase 2 trial (ChiCTR1900024428), patients with locally advanced gastric/gastroesophageal junction cancers receive one cycle of sintilimab (anti-PD1) and chemotherapy (S-1 and nab-paclitaxel), followed by 5 weeks of concurrent chemoradiotherapy and sintilimab, and ano...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Jia, Lu, Xiaofeng, Liu, Qin, Fu, Yao, Liu, Song, Zhao, Yang, Zhou, Jiawei, Chen, Hui, Wang, Meng, Li, Lin, Yang, Ju, Liu, Fangcen, Zheng, Liming, Yin, Haitao, Yang, Yang, Zhou, Chong, Zeng, Ping, Zhou, Xiaoyu, Ding, Naiqing, Chen, Shiqing, Zhao, Xiaochen, Yan, Jing, Fan, Xiangshan, Guan, Wenxian, Liu, Baorui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425436/
https://www.ncbi.nlm.nih.gov/pubmed/37580320
http://dx.doi.org/10.1038/s41467-023-40480-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425436/
https://www.ncbi.nlm.nih.gov/pubmed/37580320
http://dx.doi.org/10.1038/s41467-023-40480-x

Ejemplares similares